Corporate ActionMay 21, 2026, 05:17 PM
Sensei Biotherapeutics Stockholders to Vote on Series B Conversion
AI Summary
Sensei Biotherapeutics, Inc. announced its Annual Meeting on June 10, 2026, where stockholders will vote on the conversion of Series B Non-Voting Convertible Preferred Stock into common stock. This conversion is significant as it will represent over 20% of outstanding common stock and trigger a change of control under Nasdaq Listing Rules. The company also filed unaudited pro forma financial information for the quarter ended March 31, 2026, reflecting this conversion, which shows a pro forma net loss of $(170.2) million and a pro forma net loss per common share of $(6.62).
Key Highlights
- Annual Meeting scheduled for June 10, 2026, for stockholder vote.
- Stockholders to vote on conversion of Series B Preferred Stock into common stock.
- Conversion represents over 20% of outstanding common stock.
- Conversion to result in a change of control per Nasdaq Listing Rules.
- Pro forma net loss for Q1 2026: $(170.2) million.
- Pro forma net loss per common share for Q1 2026: $(6.62).
- Pro forma weighted-average shares outstanding: 25,729,972.
- Series B Preferred Stock originated from Faeth acquisition and $200 million PIPE financing.
Price Impact
More from SNSE